• Redwood Pharma to Present at BIO 2016 in San Francisco

    Redwood Pharma AB (publ) has been invited to the BIO 2016 conference to present Redwood Pharma’s drug candidate RP101 and drug delivery platform IntelliGel®. BIO 2016 is the world’s largest conference on biotech. The conference takes place in San Francisco, CA, USA between June 6 to 9. Over 15,000 participants will meet in San Francisco […]

  • Redwood Pharma raises SEK 6.6 million in private placement

    Stockholm, Sweden – Redwood Pharma AB has completed a SEK 6.6 million private placement to fund development of its lead product candidate RP101 for the treatment of chronic Dry Eye Disease. The active substance has been successfully tested in two human clinical Phase II studies and will now be tested in combination with IntelliGel®, the company’s […]

  • Redwood Pharma licenses novel hydrogel drug delivery technology from Broda Technologies

    Stockholm, Sweden – Redwood Pharma AB has entered into a licensing agreement with Broda Technologies Co., Ltd., operating in both the US and China, to use the company’s proprietary IntelliGel(R) supramolecular hydrogel technology in its lead chronic Dry Eye therapeutic currently under development and other ophthalmic therapies.  The Broda technology offers many unique competitive benefits.  At […]